What is Amgen's market cap?

Amgen (AMGN) has a market capitalization of $198.61B and trades on NASDAQ.

What is Amgen's revenue and profitability?

Amgen generated $37.2B in trailing twelve-month revenue with net income of $7.8B, representing a net margin of 21.0%. Gross margin stands at 68.3%, with free cash flow of $8.6B. These figures are based on the Q1 2026 filing.

Who are Amgen's competitors?

Amgen's key competitors include Eli Lilly and Company, Novo Nordisk, Regeneron Pharmaceuticals, and others. These companies compete in similar markets and product categories.

Who does Amgen partner with?

Amgen's notable partners include Kyowa Kirin, AstraZeneca.

What subsidiaries does Amgen have?

Amgen's subsidiaries include ChemoCentryx, Horizon Therapeutics.

Where is Amgen headquartered?

Amgen is headquartered in United States of America and employs approximately 26,700 people. It has been publicly traded since 1983.

Amgen

AMGN

Amgen is a global biotechnology leader focused on discovering, developing, and delivering innovative human therapeutics for serious illnesses with high unmet medical needs.

Market cap

$198.61B+23.8%

Revenue$37.2B+9.1%

Net income$7.8B+31.5%

Free cash flow$8.6B-21.2%

EPS (diluted)$14.38+31.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$8.6BBeat by $42.9M EPS$5.15Beat by $0.38

Read the full report

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$9.4B

EPS estimate$5.56

Financials

Q1 2026

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation & ratios

Valuation

See full

Market cap$198.61B+23.8%

Enterprise value$255.37B+18.2%

P/E25.5×+1.2×

P/S5.3×+0.7×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Segments

By product

See full

Other products$1.5B+3.6%

Repatha$876.0M+16.2%

Prolia$727.0M-33.8%

EVENITY$562.0M+27.1%

TEPEZZA$490.0M+28.6%

By segment

See full

Reportable Segment$8.6B+5.8%

Competitors

By market cap

Eli Lilly$1.08T+54.7%

Johnson & Johnson$634.06B+68.9%

AbbVie$446.54B+33.6%

Amgen$198.61B+23.8%

Pfizer$137.07B-5.0%

Regeneron Pharmaceuticals$69.5B+17.6%

Precigen$2.0B+315%

Opko Health$1.1B-1.3%

By revenue growth

Precigen+376%

Eli Lilly+47.4%

AbbVie+9.5%

Amgen+9.1%

Johnson & Johnson+7.9%

Regeneron Pharmaceuticals+5.9%

Pfizer+1.4%

Opko Health-15.7%

By net margin

Eli Lilly34.99%+12.3pp

Regeneron Pharmaceuticals29.65%-2.3pp

Johnson & Johnson21.83%-2.6pp

Amgen20.96%+3.6pp

Pfizer15.65%+6.3pp

AbbVie5.79%-1.5pp

Opko Health-36.64%-31.0pp

Precigen-3,655.99%+2,037pp

Profile

Amgen is a global biotechnology leader focused on discovering, developing, and delivering innovative human therapeutics for serious illnesses with high unmet medical needs. The company leverages advanced human genetics and biologics expertise to treat cardiovascular disease, oncology, inflammation, and rare diseases. Amgen operates as an independent biotechnology pioneer with a presence in approximately 100 countries.

Competitive position

A leading independent biotechnology company with a robust pipeline of first-in-class medicines and a significant global commercial footprint.

GeographiesGlobal, United States, European Union

Customer segmentsPatients, Healthcare Providers, Payors

Business modelResearch and Development, Manufacturing and Distribution

SuppliersRaw material suppliers, Clinical research organizations, Specialized laboratory equipment providers

CustomersDrug wholesalers, Retail pharmacies, Hospitals and clinics, Government health agencies

CountryUnited States of America

Listed1983

Employees26.7K

CEORobert A. Bradway

SectorHealthcare

IndustryDrug Manufacturers - General

Websiteamgen.com

FilingsSEC EDGAR

Ask your AI about Amgen.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's market cap?: Amgen (AMGN) has a market capitalization of $198.61B and trades on NASDAQ.
What is Amgen's revenue and profitability?: Amgen generated $37.2B in trailing twelve-month revenue with net income of $7.8B, representing a net margin of 21.0%. Gross margin stands at 68.3%, with free cash flow of $8.6B. These figures are based on the Q1 2026 filing.
Who are Amgen's competitors?: Amgen's key competitors include Eli Lilly and Company, Novo Nordisk, Regeneron Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does Amgen partner with?: Amgen's notable partners include Kyowa Kirin, AstraZeneca.
What subsidiaries does Amgen have?: Amgen's subsidiaries include ChemoCentryx, Horizon Therapeutics.
Where is Amgen headquartered?: Amgen is headquartered in United States of America and employs approximately 26,700 people. It has been publicly traded since 1983.